Related Experiment Video
Updated: Jun 28, 2026

09:36
Assessment of Child Anthropometry in a Large Epidemiologic Study
Published on: February 2, 2017
Reassessing BMI thresholds for obesity: a population-based study in Turkish adults
Semiha Zeynep Özsaydı1, Hasan Durmuş2, Leyla Tekdemir1
1Health Directorate of Kayseri, Kayseri, Turkey.
International Journal of Obesity (2005)
|June 26, 2026
Summary
Universal body mass index (BMI) cut-offs may underestimate obesity in Turkish adults. This study proposes new, ethnicity-specific BMI thresholds to improve obesity diagnosis and public health strategies.
Area of Science:
- Public Health
- Anthropometry
- Epidemiology
Background:
- Rising global obesity rates present significant public health challenges.
- Existing universal BMI cut-offs may not accurately assess obesity risk in diverse ethnic groups, including Turkish adults.
Purpose of the Study:
- To investigate the correlation between body mass index (BMI) and body fat percentage (BF%) in Turkish adults.
- To establish precise BMI cut-off points for obesity diagnosis tailored to the Turkish population.
Main Methods:
- Cross-sectional study involving 18-65 year olds in Kayseri, Turkey.
- Collected anthropometric data (height, weight, waist/hip circumference) and body composition via bioelectrical impedance analysis (BIA).
- Utilized Receiver Operating Characteristic (ROC) curve analysis to determine optimal BMI thresholds for obesity prediction based on BF%.
Main Results:
- A strong positive correlation was observed between BMI and BF% in both women (r=0.86) and men (r=0.68).
- Optimal BMI cut-off points for obesity were identified as 28.76 kg/m² (total), 28.80 kg/m² (women), and 28.76 kg/m² (men).
- Implementing these thresholds increased obesity prevalence from 27.7% to 33.6%, with excellent discriminative power (AUC=0.98 for women, 0.91 for men).
Conclusions:
- Current universal BMI cut-offs (≥30 kg/m²) likely underestimate obesity prevalence in the Turkish population.
- Developing national and gender-specific BMI thresholds is crucial for accurate obesity diagnosis.
- Tailored thresholds can enhance public health interventions for chronic non-communicable diseases.
Related Concept Videos
Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
